San Diego, California, July 21, 2014 – Puregraft LLC, a leader in the development and commercialization of autologous fat (adipose) grafting systems, is pleased to announce that a peer-reviewed paper evaluating the use of the Puregraft adipose filtration technology has been published in the July 2014 issue of Aesthetic Surgery Journal1.
In this study, the investigators compared the rates of graft retention (an important measure of fat grafting success) in 26 patients, or 52 hemifaces, using the Puregraft technology versus a historical study of centrifuge processed fat grafts. The mean follow-up period was 17 months and the mean amount of fat injected into the treated areas was 8.88 mL. The authors reported that the mean retention rate of 41.2% found in the Puregraft population was statistically significantly higher than the 31.8% found in the centrifuge processed samples. Further, mean retention of the Puregraft group was significantly higher (53%) in patients younger than 55 years of age. Retention rates were measured volumetrically using a 3D camera and software system.
According to facial plastic surgeon Mark Glasgold, M.D., F.A.C.S., senior author of the paper, “Fat grafting has long been criticized for its unpredictable rates of retention. Puregraft helps to address this shortcoming and performed better when compared to traditional methods of processing.” The study results are consistent with previously published results, showing that Puregraft processing was less traumatic and more efficient at removing free lipids, blood cells, and fluid as compared to centrifuge processing.
The Puregraft range of products feature sterile, single-use disposable units in three sizes (50mL, 250mL, and 850 mL), designed for optimized fat grafting to the face, body, and breast. Within 15 minutes, the surgeon can have high quality fat ready for reinjection. The advanced filtration systems effectively remove cell-damaging free lipids as well as contaminating white and red blood cells, thereby contributing to increased graft retention.
Today, the Puregraft system has been used over 30,000 times in operating rooms around the world.
“This paper highlights the fundamental value of Puregraft. It has long been believed that a cleaner graft means better take and the authors’ work has transformed this belief into clinical evidence,” commented Mr. Brad Conlan, CEO of Puregraft. “The data supporting Puregraft will continue to grow and supports our leadership position in the area of fat grafting technology.”
 Long-Term Volumetric Retention of Autologous Fat Grafting Processed With Closed-Membrane Filtration, David J. Gerth, Bethany King, Lesley Rabach, Robert A. Glasgold and Mark J. Glasgold. Aesthetic Surgery Journal published online 15 July 2014
Puregraft LLC is a San Diego-based leader in the development and commercialization of closed, sterile, fat grafting solutions. In 15 minutes or less, the company’s FDA approved and CE-Marked Puregraft technology can provide a surgeon with purified adipose tissue for reinjection. The technology is used today in hospitals and clinics around the world to provide surgeons with confidence and convenience. With the growing body of clinical data and it’s evolving product pipeline, Puregraft LLC is positioned to continue its leadership in the growing, fat grafting marketplace.
Cautionary Statement Regarding Forward-Looking Statements
This press release may include “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as “will,” “near future,” “positioned,” “provide,” or other words or phrases of similar import that are intended to identify forward-looking statements. Similarly, statements herein that describe Puregraft LLC’s business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements, including: the clinical and commercial potential and success of the company’s Puregraft product line; general economic and business conditions; and other risks and important factors that could cause actual results to differ materially from the forward-looking statements. The forward-looking statements included in this press release are made only as of the date of this announcement, and Puregraft LLC undertakes no obligation to update the forward-looking statements to reflect subsequent events or circumstances after the date on which they were made.